SCHEMBL21725671

SCHEMBL21725671

COCCOCCNCC(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.40
RECQL P46063 1/20 0.40
SCN1A P35498 1/20 0.37
SCN2A Q99250 1/20 0.37
SCN3A Q9NY46 1/20 0.37
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.33
ALDH1A1 P00352 2/20 0.32
ANPEP P15144 1/20 0.31
NPC1 O15118 1/20 0.31
POLB P06746 1/20 0.30
CTSK P43235 1/20 0.30
PIK3CD O00329 1/20 0.30
RAD52 P43351 1/20 0.30
PAX8 Q06710 1/20 0.30
CA2 P00918 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2C19 P33261 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20075871 1.00 KDM4E (0.40) KDM4ERECQLSCN1ASCN2ASCN3A
SCHEMBL22906505 1.00 KDM4E (0.40) KDM4ERECQLSCN1ASCN2ASCN3A
SCHEMBL20324094 1.00 KDM4E (0.40) KDM4ERECQLSCN1ASCN2ASCN3A
SCHEMBL20075965 1.00 KDM4E (0.40) KDM4ERECQLSCN1ASCN2ASCN3A
SCHEMBL14296394 0.89 SCN1A (0.42) SCN1ASCN2ASCN3AMEN1KMT2A
SCHEMBL20076071 0.88 CA2 (0.34) KDM4ERECQLSCN1ASCN2ASCN3A
SCHEMBL9546919 0.86
Hydrochloric Acid SCHEMBL17386606 0.84 L3MBTL1 (0.44) KDM4ERECQLSCN1ASCN2ASCN3A
SCHEMBL27838365 0.83 KDM4E (0.40) KDM4ERECQLMEN1KMT2AL3MBTL1
SCHEMBL23696283 0.83 SCN1A (0.37) KDM4ERECQLSCN1ASCN2ASCN3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220162173-A1 COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-05-26 US disclosed
US-20200385369-A1 NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS GB005 INC (US) 2020-12-10 US disclosed
US-10562893-B2 Benzimidazoles derivatives as Tec kinases family inhibitors GB005, INC. (US) 2020-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562893-B2 Benzimidazoles derivatives as Tec kinases family inhibitors BMX, TEC, BTK KDM4E 2460/4885RECQL 2148/4885SCN1A 4437/4885
US-20220162173-A1 COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT GABBR1, GABBR2, PMP22 KDM4E 2794/4885RECQL 1081/4885SCN1A 339/4885
US-20200385369-A1 NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS BMX, TEC, BTK KDM4E 2440/4885RECQL 2229/4885SCN1A 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.